Related and Nonrelated Parties [Axis] Officer [Member] Related Party [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Asset Class [Axis] Money Market Funds [Member] Investment, Name [Axis] TELI Pharmaceuticals, Inc [Member] Williams [Member] Bay Shore Trust [Member] Aminov [Member] Business Combination [Axis] Mr Aminov [Member] Class of Warrant or Right [Axis] Bay Shore Trust Warrants [Member] Legal Entity [Axis] Investigational New Drug [Member] Statistical Measurement [Axis] Maximum [Member] MIRALOGX, LLC [Member] Intangible Asset, Finite-Lived, Class [Axis] Intellectual Property [Member] Bayshore Financing [Member] Starwood Trust [Member] MIRA Pharmaceuticals, Inc [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Funding Commitment Agreement [Member] TELI Acquisition [Member] At The Market Offering Agreement [Member] Sale of Stock [Axis] At The Market Offering [Member] 2023 Private Placement [Member] Investor [Member] IPO [Member] Plan Name [Axis] 2023 Omnibus Incentive Plan [Member] Title and Position [Axis] Board Of Directors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Consultants [Member] Award Type [Axis] Installment One [Member] Installment Two [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] ASSETS Current assets: Cash Prepaid expenses Total current assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Trade accounts payable and accrued liabilities Due to related parties Accrued compensation - officer Insurance loan payable Total current liabilities Total liabilities Commitments and contingencies (Note 9) Stockholders’ Equity: Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. Common Stock, no par value; 300,000,000 shares authorized, 68,774,956 and 34,380,971 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively. Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Statement of Financial Position [Abstract] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating costs: General and administrative expenses Research and development expenses Total operating costs Interest income Interest expense Total other income, net Net loss Deemed dividend Net loss attributable to common stockholders Basic net loss per share attributable to common stockholders Diluted net loss per share attributable to common stockholders Basic weighted average common stock shares outstanding Diluted weighted average common stock shares outstanding Statement [Table] Statement [Line Items] Balance Balance, shares Stock-based compensation Net loss Issuance of common stock for cash in ATM, net Issuance of common stock for cash in ATM, net, shares Stock-based compensation – stock option modification Issuance of common stock – TELI acquisition Issuance of common stock - TELI acquisition, shares Issuance of common stock for cash, Related party Issuance of common stock for cash, Related party, shares Issuance of common stock for services Issuance of common stock for services, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from Operating activities: Adjustments to reconcile net loss to net cash used in operations Stock-based compensation expense Stock-based compensation expense – stock option modification Change in operating assets and liabilities: Prepaid expenses Trade accounts payable and accrued liabilities Accrued compensation - officer Net cash used in operating activities Cash flows from Financing activities: Repayment to officer Proceeds from issuance of insurance loan payable Repayments on insurance loan payable Proceeds from TELI contribution, related party Repayment of payable to related party Net proceeds from sale of common stock in ATM Proceeds from sale of common stock Net cash provided by financing activities Net change in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for income tax Accounting Policies [Abstract] Description of business Summary of Significant Accounting Policies Prepaid Expenses Prepaid expenses Fair Value Disclosures [Abstract] Fair value measurements Related Party Asset Acquisition Of Teli Related Party Asset Acquisition of TELI License Agreement Related Party License agreement, related party Related Party Transactions [Abstract] Related parties’ balances and transactions Insurance Loan Payable Insurance loan payable Commitments and Contingencies Disclosure [Abstract] Commitments and contingencies Equity [Abstract] Stockholders’ equity Segment Reporting [Abstract] Segment Information Subsequent Events [Abstract] Subsequent Events Basis of presentation Liquidity and going concern Certain risks and uncertainties Revenue recognition Income taxes Research and development expenses Use of estimates Cash and Cash Equivalents Stock-based compensation Warrants Fair Value Measurements and Financial Instruments Loss per Share Recent accounting pronouncements Schedule of common stock equivalents were excluded from computation of diluted net loss per share Schedule of prepaid expense and other current assets Schedule of fair value hierarchy of the valuation inputs Schedule of Warrant Activity Schedule of Stock Option Activity Schedule of segment information AccountingPoliciesTable [Table] Aggregate restricted shares of common stock Cash in operations Net losses Stockholders equity Cash, FDIC insured amount Cash, uninsured amount Deemed dividend Shares issued in connection with acquisition Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common Stock equivalents were excluded from the computation of the diluted net loss per share Schedule Of Prepaid Expense And Other Current Assets Prepaid expense: Prepaid insurance Other prepaid expense Total prepaid expenses Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Money Market Account DisclosureRelatedPartyAssetAcquisitionOfTeliTable [Table] Beneficially owned percentage Percentage of acquire outstanding equity interests Beneficially owned percentage Commitment to invest related to clinical milestones Fund commitment, description Contribution amount Exchange of shares Common stock calculated value Common stock calculated value per share Shares issued value Historical carrying value Deemed dividend Net increase in shareholders equity LicenseAgreementRelatedPartyDetailsNarrativeTable [Table] Ownership percentage Percentage of royalty payable Royalty payment Related Party Transaction [Table] Related Party Transaction [Line Items] Accrued compensation officer Amount advanced to remitting employee payroll Service provider for ongoing research cost Intellectual property development costs Amount due from related parties Raised amount in equity financing Number of restricted shares issued Purchase price per share Premium share price percentage Purchase price per share Initial payment Aggregate borrowings amount Interest rate Common stock acquisitions Long-Term Purchase Commitment, Amount Insurance loan payable Insurance monthly payments Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Development in process Initial funding commitment payable Second funding commitment payable Numbe shares issued Plaintiff claims damages Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Warrants Outstanding, Beginning Balance Weighted Average Exercise Price, Outstanding Beginning Balance Weighted Average Remaining Contractual Term (Years), Outstanding Balance Aggregate Intrinsic Value, Outstanding Beginning Balance Number of Warrants, Granted Weighted Average Exercise Price, Granted Number of Warrants, Exercised Weighted Average Exercise Price, Exercised Number of Warrants Outstanding, Ending Balance Weighted Average Exercise Price, Outstanding Ending Balance Aggregate Intrinsic Value, Outstanding Ending Balance Number of Shares, Outstanding Weighted Average Exercise Price Per Share, Outstanding Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value, Outstanding Number of Shares, Options Granted Weighted Average Exercise Price Per Share, Options Granted Number of Shares, Forfeitures/Expired Weighted Average Exercise Price Per Share, Forfeitures/Expired Number of Shares, Outstanding Weighted Average Exercise Price Per Share, Outstanding Aggregate Intrinsic Value, Outstanding Number of stock option, Vested and exercisable Weighted average exercise price, Vested and exercisable Weighted average remaining contractual life (years), Vested and exercisable Aggregate intrinsic value, Vested and exercisable Issue of shares of capital stock Net increase to additional paid-in capital Aggregate offering amount Common stock shares Weighted average price Proceeds from issuance or sale of equity Proceeds from issuance of common stock Stock price Vested common shares service Vested common shares service, value Warrants issued Warrants remaining contractual term Common stock are reserved for issuance Stock options modification Stock options modification Stock options granted Option grant date Risk-free interest rate Expected volatility Dividend yield Expected term Stock-based compensation Unrecognized compensation costs Other income (expense): Number of reportable segment Subsequent Event [Table] Subsequent Event [Line Items] Modification on certain outstanding stock options Stock option granted Vesting percentage Increase decrease in accrued compensation. Proceeds from repayments of officer. Proceeds from issuance of insurance loan payable. Repayments on insurance loan payable. Stock-based compensation expense – stock option modification. Net proceeds from sale of common stock in ATM. Liquidity And Going Concern [Policy Text Block] Certain Risks And Uncertainties [Policy Text Block] Warrants [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted [Policy Text Block] Prepaid Expenses [Text Block] TELI Pharmaceuticals, Inc [Member] Bay Shore Trust Warrants [Member] Investigational New Drug [Member] Shares issued value. Historical carrying value. Bay Shore Trust [Member] Common stock calculated value. Common stock calculated value per share. License Agreement Related Party [Text Block] MIRALOGX, LLC [Member] Percentage of royalty payable. Payment of development costs. Share based compensation arrangement by share based payment award price of common stock percent. Bayshore Financing [Member] Starwood Trust [Member] MIRA Pharmaceuticals, Inc [Member] Related Party Asset Acquisition [Text Block] Insurance Loan Payable Disclosure [Text Block] Financing institution insurance policies amount. Payment of insurance amount. TELI Acquisition [Member] At The Market Offering Agreement [Member] At The Market Offering [Member] Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2 2023 Private Placement [Member] 2023 Omnibus Incentive Plan [Member] Board Of Directors [Member] Modification on certain outstanding stock options. Consultants [Member] Installment One [Member] Installment Two [Member] Schedule Of Segment Information By Segment [Text Block] Deemed dividend. Assets, Current Assets Liabilities, Current Liabilities Liabilities and Equity Operating Expenses Interest Expense, Nonoperating Other Nonoperating Income (Expense) Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable and Accrued Liabilities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation RepaymentsOnInsuranceLoanPayable Repayments of Related Party Debt Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Prepaid Expenses [Text Block] Insurance Loan Payable Disclosure [Text Block] Research and Development Expense, Policy [Policy Text Block] Share-Based Payment Arrangement [Policy Text Block] EquityMethodInvestmentOfBeneficiallyOwnershipPercentage FinancingInstitutionInsurancePoliciesAmount Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Employee Benefits and Share-Based Compensation Share-Based Payment Arrangement, Expense